BICO Reports Q3 Growth, Impairs Biosero Assets and Refocuses Strategy
BICO reported Q3 2026 growth and profitability, impaired remaining Biosero goodwill and technology, and plans to reduce exposure to large-scale integrated Lab Automation. The results were supported by previously announced SCIENION agreements.
BICO reported Q3 2026 growth and profitability, supported by previously announced SCIENION agreements. It impaired remaining Biosero goodwill and technology and plans to reduce exposure to large-scale integrated Lab Automation.Material DetailsContext by AI AnalystThis is a Q3 results update paired…